These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3295623)

  • 1. [Prospective controlled study of therapy of chronic myeloid leukemia (CML)].
    Hehlmann R; Heimpel H; Hossfeld DK; Köpcke W; Kolb HJ; Löffler H; Pralle H; Queisser W; Anger B; Bergmann L
    Onkologie; 1987 Feb; 10(1):28-33. PubMed ID: 3295623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy of chronic myelocytic leukemia. Status of the German Multicenter Study on busulfan versus hydroxyurea versus alpha interferon, October 1897].
    Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H
    Onkologie; 1988 Feb; 11(1):25-9. PubMed ID: 3283622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.
    Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H
    Blut; 1988 Feb; 56(2):87-91. PubMed ID: 3277680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of chronic myelogenous leukemia.
    Griffin JD
    Semin Hematol; 1986 Jul; 23(3 Suppl 1):20-6. PubMed ID: 3526559
    [No Abstract]   [Full Text] [Related]  

  • 5. [Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)].
    Hehlmann R; Heimpel H; Heinze B; Georgii A; Kolb HJ; Hossfeld DK; von Wussow P; Hochhaus A; Griesshammer M; Diehl V
    Onkologie; 1991 Feb; 14(1):66-73. PubMed ID: 2057176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Ph'-positive chronic myelogenous leukemia (CML) with recombinant interferon alfa-2b (Intron A).
    Alimena G; Morra E; Lazzarino M; Liberati AM; Montefusco E; Inveradi D; Bernasconi P; Mancini M; Grignani F; Bernasconi C
    Cancer Treat Rev; 1988 Jan; 15 Suppl A():21-6. PubMed ID: 3277708
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
    Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Heinze B; Georgii A
    Blood; 1993 Jul; 82(2):398-407. PubMed ID: 8329700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Chronic myeloid leukemia trialists' collaborative group.
    Br J Haematol; 2000 Sep; 110(3):573-6. PubMed ID: 10997966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia.
    Bolin RW; Robinson WA; Sutherland J; Hamman RF
    Cancer; 1982 Nov; 50(9):1683-6. PubMed ID: 6956430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia.
    Rushing D; Goldman A; Gibbs G; Howe R; Kennedy BJ
    Am J Clin Oncol; 1982 Jun; 5(3):307-13. PubMed ID: 6952759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
    Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
    Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea therapy in chronic myelogenous leukemia.
    Kennedy BJ
    Cancer; 1972 Apr; 29(4):1052-6. PubMed ID: 4552811
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon alfa-2b in the management of chronic granulocytic leukemia.
    Bergsagel DE
    Cancer Treat Rev; 1988 Jan; 15 Suppl A():15-20. PubMed ID: 3422593
    [No Abstract]   [Full Text] [Related]  

  • 15. [Two busulfan-resistant cases of CML (chronic myelogenous leukemia) with good response to alpha-interferon treatment].
    Ogura H; Shirafuji N; Kumakawa T; Matsuda S; Horiuchi N; Kodo H; Fujii H; Asano S; Miwa S; Shinohara T
    Rinsho Ketsueki; 1987 Sep; 28(9):1599-604. PubMed ID: 3481405
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic myelogenous leukemia: a clinical and experimental evaluation of splenectomy and intensive chemotherapy.
    Brodsky I; Fuscaldo KE; Kahn SB; Conroy JF; Lamping CG
    Ser Haematol; 1975; 8(4):143-56. PubMed ID: 798283
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study Group.
    Hehlmann R; Heimpel H; Griesshammer M; Kolb HJ; Heinze B; Hossfeld DK; Wickramanayake PD; Essers U; Thiele J; Georgii A
    Leukemia; 1992; 6 Suppl 3():110S-114S. PubMed ID: 1602805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Kurzrock R; Keating MJ; McCredie KB; Gutterman J; Freireich EJ
    Acta Haematol; 1987; 78 Suppl 1():70-4. PubMed ID: 2449026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.
    Talpaz M; Kantarjian HM; McCredie K; Trujillo JM; Keating MJ; Gutterman JU
    N Engl J Med; 1986 Apr; 314(17):1065-9. PubMed ID: 3457264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group.
    Hehlmann R; Kister P; Willer A; Simon M; Schenk M; Seifarth W; Papakonstantinou G; Saussele S; Kolb HJ; Ansari H
    Leukemia; 1994 Apr; 8 Suppl 1():S127-32. PubMed ID: 8152279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.